FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
AACR 2024 – Akeso impresses in stomach cancer
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
